Matches in Nanopublications for { ?s ?p "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP368865.RATdUEOaIJTryg0OnQ9dIPWosUGF4cZ1815Xh4oSXxIto130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368865.RATdUEOaIJTryg0OnQ9dIPWosUGF4cZ1815Xh4oSXxIto130_provenance.
- assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1169932.RAixH4tcbUMkUUsJrYSkqZU_NEx83irq18Ex4n874rrjA130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1169932.RAixH4tcbUMkUUsJrYSkqZU_NEx83irq18Ex4n874rrjA130_provenance.
- NP1169935.RAsb7hQvzNHRWhMssaBJT10nUhHmvwoqvTIxq7YW9uIvE130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1169935.RAsb7hQvzNHRWhMssaBJT10nUhHmvwoqvTIxq7YW9uIvE130_provenance.
- NP543298.RAEa9K6TatRYzlAhu9y4hE85iF9FkQlRA8UL3cZZfyhDM130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP543298.RAEa9K6TatRYzlAhu9y4hE85iF9FkQlRA8UL3cZZfyhDM130_provenance.
- NP543239.RA_NK7x8hAcezby9TkFyq3iFq9V1Tyt1zRRGwX8lsFTe4130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP543239.RA_NK7x8hAcezby9TkFyq3iFq9V1Tyt1zRRGwX8lsFTe4130_provenance.
- NP543464.RA6re6ucprm7maeO8hOYYLqFGgIHXXeC1liSteI1NF68Q130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP543464.RA6re6ucprm7maeO8hOYYLqFGgIHXXeC1liSteI1NF68Q130_provenance.
- NP370668.RANmpWj_TzXZUgPXGbMBtJCE8tHeYbAp3_p_lguQmH1Kk130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP370668.RANmpWj_TzXZUgPXGbMBtJCE8tHeYbAp3_p_lguQmH1Kk130_provenance.
- NP1169930.RAxkZxt41XNUN_oaCk9gunncFZG2RyhpljmrKEfC1IKzM130_assertion description "[These results suggest that efatutazone inhibits cell motility by antagonizing the TGF-?/Smad2 pathway and effectively prevents metastasis in NSCLC patients with acquired resistance to EGFR-TKI regardless of the resistance mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1169930.RAxkZxt41XNUN_oaCk9gunncFZG2RyhpljmrKEfC1IKzM130_provenance.